Sionna Therapeutics Inc
Research Sionna Therapeutics Inc (SION) on Bullrun: market cap USD 211.82M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSION
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 211.82M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 29.89M
- Free cash flow-USD 22.22M
Valuation Snapshot
latest market cap is USD 211.82M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 75.27M | -USD 66.67M | n/a | -1.88 | USD 58.45M | USD 8.68M | USD 306.83M |
| FY2024 | USD 0 | -USD 61.69M | -USD 52.81M | n/a | -15.99 | USD 37.79M | USD 9.75M | -USD 163.71M |
| FY2023 | USD 0 | -USD 47.26M | -USD 44.82M | n/a | -1.7 | USD 38.52M | USD 10.48M | -USD 114.88M |
| FY2022 | USD 0 | -USD 40.24M | -USD 37.94M | n/a | -2.32 | USD 54.84M | USD 0 | -USD 69.92M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 211.82M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.84B | n/a | n/a | n/a |
About Sionna Therapeutics Inc
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sionna Therapeutics Inc's market cap?
Sionna Therapeutics Inc's market capitalization is USD 211.82M.
What does Sionna Therapeutics Inc do?
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).